Moyo, SPuren, ASimbayi, LZuma, KZungu, NMarinda, EJooste, SFortuin, MBrukwe, ZSingh, BMabaso, MReddy, TParker, WNaidoo, IManda, SGoga, ANgandu, NCawood, CMorris, LMoore, PRehle, T2025-03-022025-03-022022-0310.13140/RG.2.2.35310.89926https://hdl.handle.net/11288/598206Poster presented at the Conference on Retroviruses and Opportunistic Infections (CROI), 12-16 February 2022.In this paper we present results from the first national house-hold based SARS CoV- 2 sero-prevalence survey conducted in South Africa in 2020-21. The survey used a cross-sectional multi-stage stratified cluster design. The data was collected over two separate time periods (November 2020 - February 2021 and April - June 2021). This periods coincided with the second and third waves of the pandemic in South Africa. In this paper we compare the performance of the The Abbott® and Euroimmun® ani-SARS CoV- 2 antibody assays.enAttribution-NonCommercial-NoDerivs 3.0 United Stateshttp://creativecommons.org/licenses/by-nc-nd/3.0/us/South AfricaSARS-CoV-2Household serosurveyPresentation